In today’s recent session, 251.76 million shares of the ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) have been traded, and its beta is 0.21. Most recently the company’s share price was $0.73, and it changed around $0.24 or 48.44% from the last close, which brings the market valuation of the company to $22.73M. IPA at last check was trading at a discount to its 52-week high of $2.60, offering almost -256.16% off that amount. The share price’s 52-week low was $0.32, which indicates that the recent value has risen by an impressive 56.16% since then. We note from ImmunoPrecise Antibodies Ltd’s average daily trading volume that its 10-day average is 0.48 million shares, with the 3-month average coming to 625.50K.
ImmunoPrecise Antibodies Ltd stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended IPA as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. ImmunoPrecise Antibodies Ltd is expected to report earnings per share of 0 for the current quarter.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) trade information
Instantly IPA has been showing a green trend so far today with a performance of 48.44% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.9244 on recent trading dayincreased the stock’s daily price by 21.03%. The company’s shares are currently up 77.75% year-to-date, but still up 59.09% over the last five days. On the other hand, ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) is 69.01% up in the 30-day period. We can see from the shorts that 0.69 million shares have been sold at a short interest cover period of 0.7 day(s).
ImmunoPrecise Antibodies Ltd (IPA) estimates and forecasts
ImmunoPrecise Antibodies Ltd share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -13.91 percent over the past six months and at a 65.38% annual growth rate that is well above the industry average of 25.20%. The year-over-year growth rate is expected to be 0.92%, up from the previous year.
Consensus estimates provided by 2 financial analysts predict the company will bring in an average of 6.58M in revenue for the current quarter. 2 analysts expect ImmunoPrecise Antibodies Ltd to make 6.77M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 6.22M and 6.46M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 5.85%. Forecasts for the next quarter put sales growth at 4.81%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -11.23%.
IPA Dividends
ImmunoPrecise Antibodies Ltd’s next quarterly earnings report is expected to be released in February.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 12.06% of ImmunoPrecise Antibodies Ltd shares, and 6.58% of them are in the hands of institutional investors. The stock currently has a share float of 7.48%. ImmunoPrecise Antibodies Ltd stock is held by 20.0 institutions, with INGALLS & SNYDER LLC being the largest institutional investor. By 2024-06-30, it held 5.0209% of the shares, which is about 1.3 million shares worth $1.31 million.
RENAISSANCE TECHNOLOGIES LLC, with 0.2477% or 63910.0 shares worth $64549.0 as of 2024-06-30, holds the second largest percentage of outstanding shares.
The former held 10.67 shares worth $8855.0, making up 0.04% of all outstanding shares.
